<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608019</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-PEDS</org_study_id>
    <nct_id>NCT04608019</nct_id>
  </id_info>
  <brief_title>Streamlined Treatment of Pulmonary Exacerbations in Pediatrics</brief_title>
  <acronym>STOP-PEDS</acronym>
  <official_title>Streamlined Treatment of Pulmonary Exacerbations in Pediatrics (Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington, the Collaborative Health Studies Coordinating Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington, the Collaborative Health Studies Coordinating Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STOP PEDS is a pilot study of children with CF ages 6-18 across 10 sites in North America.&#xD;
      The primary goal is to assess the acceptability and feasibility of a multicenter randomized&#xD;
      trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation&#xD;
      (PEx) treatment in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STOP PEDS is a pilot study of children with CF ages 6-18 across 10 sites in North America.&#xD;
      The primary goal is to assess the acceptability and feasibility of a multicenter randomized&#xD;
      trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation&#xD;
      (PEx) treatment in this population. The primary endpoint is the proportion of participants in&#xD;
      the tailored arm who did not take any oral antibiotics in the 28 days following&#xD;
      randomization.&#xD;
&#xD;
      Ultimately, we want to learn:&#xD;
&#xD;
        -  What is the best way to treat pulmonary exacerbations?&#xD;
&#xD;
        -  Should everyone with a pulmonary exacerbation take antibiotics?&#xD;
&#xD;
        -  Do the benefits of starting antibiotics at the first signs of illness outweigh the&#xD;
           possible risks, like side effects and antibiotic resistance?&#xD;
&#xD;
      This pilot study is designed to determine if an interventional study to help answer these&#xD;
      questions is feasible. Up to 120 participants will be enrolled and followed through their&#xD;
      well state of health, then for 28 days following their first randomized exacerbation.&#xD;
      Enrollment will stop after 80 pulmonary exacerbation events have been randomized, even if&#xD;
      this does not require 120 participants. Due to the nature of the study, the identity of&#xD;
      treatment assignment will be known to investigators, research staff, and patients (ie, not&#xD;
      blinded).&#xD;
&#xD;
      Total duration of this pilot study is expected to be approximately 18 months: 6 months for&#xD;
      participant recruitment and 12 months for follow up. Participants could be monitored for up&#xD;
      to 18 months if they do not have an exacerbation. However, it is anticipated that the&#xD;
      majority of participants will experience a randomizable PEx event and therefore have a&#xD;
      shorter follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed antibiotics</measure>
    <time_frame>28 days</time_frame>
    <description>The proportion of participants in the tailored arm who did not take any oral antibiotics in the 28 days following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consent</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of approached patients consenting to enroll</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbations Reported</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of Pulmonary Exacerbations in which symptoms are reported within 7 days of onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomization Criteria</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of Pulmonary Exacerbation events meeting randomization criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Exacerbations</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of enrolled participants experiencing a randomizable Pulmonary Exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Exacerbations</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of randomizable Pulmonary Exacerbations that undergo randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 Follow-up</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of participants with a randomized Pulmonary Exacerbation that attends an in-person Day 28 follow up visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Immediate Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>increased airway clearance plus early initiation of oral antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tailored Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immediate Antibiotics</intervention_name>
    <description>increase airway clearance/start oral antibiotics right away</description>
    <arm_group_label>Immediate Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tailored Treatment</intervention_name>
    <description>increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Enrollment Inclusion Criteria:&#xD;
&#xD;
          1. Age 6 to &lt;19 years&#xD;
&#xD;
          2. Documentation of a CF diagnosis as evidenced by one or more clinical features&#xD;
             consistent with the CF phenotype and one or more of the following criteria:&#xD;
&#xD;
               1. sweat chloride ≥ 60 mEq/liter&#xD;
&#xD;
               2. two disease-causing variants in the cystic fibrosis transmembrane conductive&#xD;
                  regulator (CFTR) gene&#xD;
&#xD;
          3. Written informed consent (and assent when applicable) obtained from participant or&#xD;
             participant's legal representative and ability of participant to comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          4. Able to perform acceptable and reproducible spirometry&#xD;
&#xD;
          5. FEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference&#xD;
             equations&#xD;
&#xD;
          6. At least 1 course of oral or IV antibiotics for respiratory symptoms since January 1,&#xD;
             2019.&#xD;
&#xD;
          7. Ability to receive text messages and access the internet&#xD;
&#xD;
        Enrollment Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          2. Previous randomization in the study&#xD;
&#xD;
          3. Receiving antibiotics for a PEx at the time of enrollment or within the 21 days prior&#xD;
             to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics&#xD;
             if they are at their baseline state of health, per self-report.&#xD;
&#xD;
          4. Treatment with systemic corticosteroids at enrollment. Individuals may be re- screened&#xD;
             ≥21 days after completion of systemic corticosteroids if they are at their clinical&#xD;
             baseline, per self-report.&#xD;
&#xD;
          5. History of solid organ transplant&#xD;
&#xD;
          6. History of positive culture for Mycobacterium abscessus in the 12 months prior to&#xD;
             enrollment&#xD;
&#xD;
          7. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment&#xD;
&#xD;
          8. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment&#xD;
&#xD;
          9. Treatment with chronic oral antibiotics other than azithromycin at enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B. Sanders, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riley Children's Hospital, Indianapolis, IN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Rosenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital, Seattle, WA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Traci Bartz, MS</last_name>
    <phone>(206) 897-1904</phone>
    <email>bartzt@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Enright</last_name>
    <phone>(206) 897-1922</phone>
    <email>eenright@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Cystic Fibrosis Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth (Lisa) Ryan</last_name>
      <phone>520-626-3125</phone>
      <email>elizabethryan@arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Pimentel</last_name>
      <phone>520-621-1806</phone>
      <email>jrpimentel@arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cori Daines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Cross</last_name>
      <phone>720-777-4645</phone>
      <email>Mary.Cross@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Dana Coyle</last_name>
      <phone>720-777-6162</phone>
      <email>dana.coyle@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordana Hoppe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akele Carter</last_name>
      <phone>404-785-9011</phone>
      <email>Akele.carter@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashleigh Streby</last_name>
      <phone>404-727-0305</phone>
      <email>ashleigh.streby@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Kirchner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago &amp; Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Wu</last_name>
      <phone>312-227-2473</phone>
      <email>yhwu@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Larissa Rugg</last_name>
      <phone>312-227-6865</phone>
      <email>lrugg@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Dowell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Thompson, B.S.</last_name>
      <phone>317-274-7768</phone>
      <email>misthomp@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Bendy</last_name>
      <phone>317-948-7152</phone>
      <email>lbendy@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>D. B. Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Symington, RN</last_name>
      <phone>616-391-9366</phone>
      <email>thomas.symington@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Kamphuis, RN</last_name>
      <phone>616-267-2022</phone>
      <email>Lindsey.Kamphuis@spectrumealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Millard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierce Nusbaum</last_name>
      <phone>503-418-1169</phone>
      <email>nusbaum@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brendan Klein</last_name>
      <phone>503-418-8108</phone>
      <email>kleinb@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelvin MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nagg, RN</last_name>
      <phone>412-692-5389</phone>
      <email>jennifer.nagg@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adrienne DeRicco</last_name>
      <phone>412-692-8069</phone>
      <email>Adrienne.Dericco2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital and Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Hernandez</last_name>
      <phone>832-822-3389</phone>
      <email>rogeliog@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katie Howe</last_name>
      <phone>(810) 429-1721</phone>
      <email>klhowe@texaschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Fadel Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon McNamara</last_name>
      <phone>206-987-3921</phone>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Gracia Bridges</last_name>
      <phone>206-987-2803</phone>
      <email>gracia.bridges@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bradley J, McAlister O, Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J. 2001 Apr;17(4):712-5.</citation>
    <PMID>11401068</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>oral antibiotics</keyword>
  <keyword>pulmonary exacerbation</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

